Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer

Louie, 2002, Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998, J Infect Dis, 186, 1023, 10.1086/343862 Mocroft, 2002, Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study, AIDS, 16, 1663, 10.1097/00002030-200208160-00012 Engels, 2001, Human immunodeficiency virus infection, aging, and cancer, J Clin Epidemiol, 54, S29, 10.1016/S0895-4356(01)00444-9 Bonnet, 2004, Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy, Cancer, 101, 317, 10.1002/cncr.20354 Engels, 2006, Trends in cancer risk among people with AIDS in the United States 1980–2002, AIDS, 20, 1645, 10.1097/01.aids.0000238411.75324.59 Herida, 2003, Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients, J Clin Oncol, 21, 3447, 10.1200/JCO.2003.01.096 Cadranel, 2006, Lung cancer in HIV infected patients: facts, questions and challenges, Thorax, 61, 1000, 10.1136/thx.2005.052373 Lavole, 2006, Lung cancer, a new challenge in the HIV-infected population, Lung Cancer, 51, 1, 10.1016/j.lungcan.2005.09.001 Chaturvedi, 2007, Elevated risk of lung cancer among people with AIDS, AIDS, 21, 207, 10.1097/QAD.0b013e3280118fca Engels, 2006, Elevated incidence of lung cancer among HIV-infected individuals, J Clin Oncol, 24, 1383, 10.1200/JCO.2005.03.4413 Parker, 1998, AIDS-related bronchogenic carcinoma: fact or fiction?, Chest, 113, 154, 10.1378/chest.113.1.154 Alshafie, 1997, Human immunodeficiency virus and lung cancer, Br J Surg, 84, 1068, 10.1002/bjs.1800840808 Brock, 2006, Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care, J Acquir Immune Defic Syndr, 43, 47, 10.1097/01.qai.0000232260.95288.93 Karp, 1993, Lung cancer in patients with immunodeficiency syndrome, Chest, 103, 410, 10.1378/chest.103.2.410 Sridhar, 1992, Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects, Chest, 102, 1704, 10.1378/chest.102.6.1704 Tirelli, 2000, Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors, Cancer, 88, 563, 10.1002/(SICI)1097-0142(20000201)88:3<563::AID-CNCR11>3.0.CO;2-D Vyzula, 1996, Lung cancer in patients with HIV-infection, Lung Cancer, 15, 325, 10.1016/0169-5002(95)00596-X Powles, 2003, HIV-related lung cancer—a growing concern?, Int J STD AIDS, 14, 647, 10.1258/095646203322387875 Powles, 2003, Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?, Br J Cancer, 89, 457, 10.1038/sj.bjc.6601111 Holkova, 2001, Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy, J Clin Oncol, 19, 3848, 10.1200/JCO.2001.19.18.3848 Tam, 2002, Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma, Int J Cancer, 98, 916, 10.1002/ijc.10274 Navarro, 2001, Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone, Br J Haematol, 112, 909, 10.1046/j.1365-2141.2001.02656.x Newell, 2004, Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients, Cancer, 100, 2627, 10.1002/cncr.20300 Vaccher, 2001, Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma, Cancer, 91, 155, 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B Weiss, 2006, Cancer, 106, 1560, 10.1002/cncr.21759 Evison, 1999, HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy, AIDS, 13, 732, 10.1097/00002030-199904160-00018 Antinori, 2001, Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy, AIDS, 15, 1483, 10.1097/00002030-200108170-00005 Little, 2003, Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology, Blood, 101, 4653, 10.1182/blood-2002-11-3589 Ratner, 2001, Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy, J Clin Oncol, 19, 2171, 10.1200/JCO.2001.19.8.2171 Bower, 2003, HIV-related lung cancer in the era of highly active antiretroviral therapy, AIDS, 17, 371, 10.1097/00002030-200302140-00011 Antoniou, 2005, Interactions between antiretrovirals and antineoplastic drug therapy, Clin Pharmacokinet, 44, 111, 10.2165/00003088-200544020-00001 Kivisto, 1995, The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions, Br J Clin Pharmacol, 40, 523, 10.1111/j.1365-2125.1995.tb05796.x Moyle, 1998, Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use, Drugs, 55, 383, 10.2165/00003495-199855030-00005 Kelly, 2001, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial, J Clin Oncol, 19, 3210, 10.1200/JCO.2001.19.13.3210 Scagliotti, 2002, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer, J Clin Oncol, 20, 4285, 10.1200/JCO.2002.02.068 Spira, 2004, Multidisciplinary management of lung cancer, N Engl J Med, 350, 379, 10.1056/NEJMra035536 Bertz, 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions, Clin Pharmacokinet, 32, 210, 10.2165/00003088-199732030-00004 Bardelmeijer, 2002, Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir, Cancer Res, 62, 6158 Bohme, 1995, Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL, Ann Hematol, 71, 311, 10.1007/BF01697985 Bundow, 2004, Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma, Am J Clin Oncol, 27, 81, 10.1097/01.coc.0000045921.91037.C8 Engels, 2004, Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel, Clin Pharmacol Ther, 75, 448, 10.1016/j.clpt.2004.01.001 Royer, 1996, Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs, Cancer Res, 56, 58 Schwartz, 1999, Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma, AIDS, 13, 283, 10.1097/00002030-199902040-00019